Use of Real World Evidence (RWE) by NICE
proposals for piloting new methodology, using the Systemic Anti Cancer Therapy (SACT) dataset to implement findings
NICE TA committees need to be provided with guidance on how SACT data can best be used, particularly with the advent of more managed access. This project provides further insight using eight topics with different characteristics to analyse and characterise factors that dictate whether differences between trial and SACT outcomes are likely to make a material difference to the ICERs for decision-making.
DSU Report
This report illustrates how the data provided for treatments placed in the CDF could be used in their current form, and what future recommendations regarding the best use of such data might include. Using SACT data to inform estimates of cost-effectiveness could potentially have led to altered NICE recommendations in four of the eight case studies considered. However, important limitations were noted associated with the data provided, and the strong assumptions associated with the analyses, which could impact the validity of the results and how these analyses would be interpreted by NICE Committees.